Biovail (BVF) Tops Q3 EPS by 21c, Revs Light
More News related to BVF
- Biovail (BVF) Comments on Proposed Clinical Trial for Generic Wellbutrin XL(R)
- Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial
- MedGenesis Announces Agreements With Amgen and Biovail
- Biovail to Present at JPMorgan Healthcare Conference
- Thomas Weisel Initiates Coverage on Biovail (BVF) with an Overweight
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Biovail Corporation (NYSE: BVF) reports Q3 EPS of $0.61, ex-items, 21 cents better than the analyst estimate of $0.40. Revenue for the quarter was $213 million, which compares to the estimate of $217.15 million.
Related Categories
EarningsStocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
